SETD2 and cancer: In addition, in osteosarcoma, SETD2 significantly inhibited cell growth, cancer stem cell properties, and cisplatin-induced chemoresistance through H3K36me3-mediated transcriptional activation of GSK3β and degradation of β-catenin96.